Dyslipidemia drug pipeline analysis and market forecasts to 2016
Download
1 / 4

Dyslipidemia Drug Pipeline Analysis and Market Forecasts - PowerPoint PPT Presentation

GlobalData estimated the global dyslipidemia market to be valued at $34.4 billion in 2009. It is expected to decline at a compound annual growth rate (CAGR) of approximately -4.6% from $34.4 billion in 2009 to $24.7 billion by 2016.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha

Download Presentation

Dyslipidemia Drug Pipeline Analysis and Market Forecasts

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Dyslipidemia - Drug Pipeline Analysis and Market Forecasts to 2016


The Dyslipidemia Market is Forecast to Decline until 2016

GlobalData estimated the global dyslipidemia market to be valued at $34.4 billion in 2009. It is expected to decline at a compound annual growth rate (CAGR) of approximately -4.6% from $34.4 billion in 2009 to $24.7 billion by 2016. Although the cardiovascular market expanded considerably from 2004 to 2008, growth in the seven major markets is expected to slow down from 2012. The decline is sales during this period will be due to the expiry of many leading brands’ patents. Pfizer’s Lipitor, a major blockbuster in the dyslipidemia market, is set to expire in 2011. Following the expiry of Lipitor’s patent, Simcor and Trilipix’s patents will also expire in 2011. Zetia, Vyotrin, Lescol, Livalo and Lovaza are set to expire during 2012-2014. This growth will be driven by the the launch of major new products with safety and convenience advantages such as once-daily administration and combinational therapies. Cetriad, from AstraZeneca and Abbott Laboratories, has been filed with the US FDA and is currently the most anticipated drug in the pipeline.

For further details, please click or add this link to your browser:

http://www.global-market-research-data.com/Report.aspx?ID=Dyslipidemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Competition in the Dyslipidemia Market is Strong

GlobalData found that the current competition in the dyslipidemia market is becoming intense due to the increased entry of combinational therapies and the use of statins, fibrates, niacin and omega-3 fatty acid derivatives as antidyslipidemic agents. It projects that Lipitor, Trilipix and Simcor will be the leading competitiors in the global dyslipidemia market. Pfizer, Abbott Laboratories/AstraZeneca and Merck will continue to be the market leaders until the patents on their drugs expire inbetween 2011 and 2014. The market is set to shrink following the expiry of Pfizer’s Lipitor. Also Simcor, Trilipix, Vyotrin, Zetia, Lescol, Lovaza and Livalo are all set to expire between 2011 and 2014. The dyslipidemia market is expected to shrink due to patent expiries in the near future.


For further details, please click or add this link to your browser:

http://www.global-market-research-data.com/Report.aspx?ID=Dyslipidemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Current Treatment Options are Moderately Successful in Meeting the Market Demand by offering Symptomatic Treatments

GlobalData has found that the available treatment options have been moderately successful in meeting the market demand. The current therapeutics are competing to provide rapid decreases in LDL-C (low density lipoprotein-cholesterol), TG (tryglycerides), TC (total cholesterol) levels and increases in HDL-C (high density lipoprotein-cholesterol) levels and improve patients’ overall quality of life. The drugs approved for the treatment of dyslipidemia can prevent cardiovascular disorders. Overall, there is strong competition among the currently marketed products based on providing symptomatic treatment of the disease. Though dyslipidemia treatments are only symptomatic, they treat patients effectively. Hence the market for dyslipidemia treatments is strong. However, safety remains a concern as antidyslipidemic drugs are associated with serious adverse effects such as myopathy or rhabdomylosis, liver disease and increased liver enzymes. There is a lot of market potential for any new entrant that can cater to these unmet needs. A product with disease modifying mechanisms and a better safety profile and good efficacy is sure to achieve blockbuster drug status by targetting these existing unmet needs. Thus, a strong opportunity exists for any drug that offers better efficacy and safety than is provided by the current players.

GlobalData, the industry analysis specialist, has released a new report, “Dyslipidemia - Drug Pipeline Analysis and Market Forecasts to 2015.” The report is an essential source of information and analysis on the global dyslipidemia disease market. The report identifies the key trends shaping and driving the global dyslipidemia disease market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dyslipidemia sector.


For further details, please click or add this link to your browser:

http://www.global-market-research-data.com/Report.aspx?ID=Dyslipidemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportstore

Contact Information:

Rajesh Gunnam

rgunnam@globaldata.com

+914066166782


ad
  • Login